

**Media Release**

**Straumann Group acquires 30% stake in botiss**

- *Companies to build further on successful partnership*
- *Straumann secures access to botiss' technology and tightens cooperation*
- *botiss benefits from Straumann's global distribution and supply network, regulatory resources, and strength as a total solution provider*

**Basel, 4 July 2018** – The Straumann Group has acquired a 30% stake in its biomaterials partner botiss medical AG for an undisclosed sum. botiss is a fast-growing, entrepreneurial company that has already become a leading provider of biomaterials for oral surgery. The acquisition agreement enables Straumann to expand its global distribution network of botiss products.

Like the Group's investment in its CAD/CAM prosthetics partner Createch (announced today in a separate release), this investment is a further step in the Group's strategy to become a total solution provider in tooth replacement and esthetic dentistry.

**Marco Gadola, Chief Executive Officer of the Straumann Group**, commented: *"botiss has boosted our biomaterials business over the past four years and enables us to offer an unparalleled range of innovative regenerative solutions to support implant and periodontal procedures. As a key shareholder, we can now contribute to developing and shaping their business. At the same time, we have secured access to their products and technology, which provides a firm basis for us to invest in growing the business further"*.

**Oliver Bielenstein, Founding and Managing Partner of botiss**, noted: *"The partnership between our two companies has created a driving force in dental biomaterials. We are delighted and proud that Straumann has decided to deepen our collaboration. By combining further resources, we will make our current solutions available to more doctors around the world and will add further innovations to enhance treatment options and outcomes"*.

**Partners since 2014**

The fact that approximately half of dental implant procedures require bone graft and membrane materials prompted the two companies to join forces in 2014, with the goal of providing complete oral tissue regeneration solutions worldwide. The agreement provided Straumann with exclusive distribution rights for botiss regenerative products in most European countries and the Americas. In 2016, the partnership deepened as Straumann took over the distribution of botiss products in Germany as well as its domestic sales team.

The two partners have collaborated to obtain regulatory approvals and expect to launch botiss products in North America, Asia/Pacific and India in the next two years. In the first quarter of this year, the Group very successfully launched the botiss range in Brazil. botiss is financially successful and, as a shareholder with a non-controlling stake, Straumann will recognize its share of botiss' earnings as 'income from associates'.

**About botiss**

Based in Berlin, botiss biomaterials is a leading international supplier of oral tissue regeneration products. Its full range of clinically-proven, high quality solutions includes membranes for guided tissue and bone regeneration, a

full range of bovine, allogenic and synthetic bone-graft materials, as well as soft-tissue-graft products. botiss is a fast-growing entrepreneurial company, whose products are used in leading clinics across Europe and are backed by many years of clinical experience. The company prides itself in innovations, such as its maxgraft® bonering for simultaneous implant placement and bone augmentation, as well as its maxgraft® bonebuilder, a CAD/CAM bone block customized for individual patients. The company has a promising innovation pipeline, which should further differentiate it as a leader in regenerative dentistry. botiss is privately owned and was founded in 2008 by Managing Partners Oliver Bielenstein and Dr. Dražen Tadić.

**About the Straumann Group**

With botiss and its other partners, the Straumann Group offers an unparalleled range of regenerative solutions to support implant and periodontal procedures. The great advantage for customers is that they can obtain total solutions conveniently from a single provider together with service and support.

The Straumann Group (SIX: STMN) is a global leader in tooth replacement and orthodontic solutions that restore smiles and confidence. It unites global and international brands that stand for excellence, innovation and quality in replacement, corrective and digital dentistry, including Straumann, Neodent, Medentika, ClearCorrect, Dental Wings, and other fully/partly owned companies and partners. In collaboration with leading clinics, institutes and universities, the Group researches, develops, manufactures and supplies dental implants, instruments, CAD/CAM prosthetics, digital and orthodontic solutions as well as biomaterials for applications in replacement, restorative, esthetic and preventative dentistry.

Headquartered in Basel, Switzerland, the Group currently employs approx. 5000 people worldwide and its products, solutions and services are available in more than 100 countries through a broad network of distribution subsidiaries and partners.

---

**Straumann Holding AG**, Peter Merian-Weg 12, 4002 Basel, Switzerland.

Phone: +41 (0)61 965 11 11 / Fax: +41 (0)61 965 11 01

Homepage: [www.straumann-group.com](http://www.straumann-group.com)

**Contacts:**

**Corporate Communication**

Mark Hill: +41 (0)61 965 13 21  
Thomas Konrad: +41 (0)61 965 15 46  
E-mail: [corporate.communication@straumann.com](mailto:corporate.communication@straumann.com)

**Investor Relations**

Fabian Hildbrand: +41 (0)61 965 13 27  
E-mail: [investor.relations@straumann.com](mailto:investor.relations@straumann.com)

**Disclaimer**

This release contains certain forward-looking statements that reflect the current views of management. Such statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the Straumann Group to differ materially from those expressed or implied in this release. Straumann is providing the information in this release as of this date and does not undertake any obligation to update any statements contained in it as a result of new information, future events or otherwise.

# # #